Seaport Therapeutics Advances GlyphAgo into Phase 2a Trial for…

Event summary

Seaport Therapeutics dosed the first patient in a Phase 2a trial for GlyphAgo, targeting generalized anxiety disorder (GAD) and sleep disturbance.
The six-week trial in Australia aims to establish proof-of-pharmacology by evaluating GlyphAgo's effects on sleep and anxiety symptoms.
GlyphAgo, a novel prodrug of agomelatine, demonstrated a 6.8-fold increase in bioavailability compared to unmodified agomelatine in Phase 1 trials.
Seaport plans to initiate a global Phase 2/3 trial in the first half of 2027, with topline data expected by the end of 2028.

The big picture

Seaport Therapeutics' advancement of GlyphAgo into Phase 2a trials marks a significant step in addressing the unmet needs in treating generalized anxiety disorder and sleep disturbances. With over 300 million people affected by anxiety disorders globally, the potential market for effective and well-tolerated treatments is substantial. The company's proprietary Glyph™ platform aims to overcome the bioavailability and hepatic limitations of existing therapies, positioning GlyphAgo as a potential game-changer in the neuropsychiatric drug space.

What we're watching

Clinical Efficacy: Whether GlyphAgo can demonstrate superior efficacy and tolerability compared to existing treatments like benzodiazepines and SSRIs.
Regulatory Pathway: The pace at which Seaport can navigate regulatory approvals for GlyphAgo, given the historical limitations of agomelatine.
Market Potential: How GlyphAgo's potential to reduce liver exposure and improve bioavailability could position it as a leading treatment for GAD.